Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Interim analysis of PRO-MIND: Consistent quality of life in elderly patients with R/R DLBCL receiving tafasitamab and lenalidomide

Pier Luigi Zinzani, Maria Cox, Flaminia Bellisario, Andrea Bernardelli, Maurizio Musso, Guido Gini, Alice Di Rocco, Eliana Liardo, Enrico Derenzini, Elsa Pennese, Nicola Battaglia, Mario Lapecorella, Antonio Pinto

Blood (2025) 146 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2025-7248

Published: 2025

Journal Articles

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Blood (2025) 146 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2025-2569

Published: 2025

Journal Articles

Daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly diagnosed patients with light-chain amyloidosis: Interim analysis from an Italian, multicenter, retro-prospective real-world experience

Blood (2025) 146 (Supplement 1): 828.

https://doi.org/10.1182/blood-2025-828

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Blood (2025) 146 (Supplement 1): 5502.

https://doi.org/10.1182/blood-2025-5502

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2025-4288

Published: 2025

Journal Articles

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Mariangela Di Trani, Cristina Skert, Loredana Elia, Giada Almici, Irene Della Starza, Deborah Cardinali, Vittorio Bellomarino, Stefano Soddu, Monica Messina, Martina Rachele Marino, Maria Stefania De Propris, Erika Borlenghi, Francesco Di Raimondo, Michela Ansuinelli, Caterina Alati, Daniele G. Mattei, Valentina Mancini, Patrizia Chiusolo, Barbara Scappini, Maria Paola Martelli, Prassede Salutari, Marco Cerrano, Bianca Serio, Antonella Cucca, Mario Luppi, Daniele Vallisa, Crescenza Pasciolla, Claudio Romani, Martina Chiarucci, Federico Mosna, Massimiliano Bonifacio, Nicola Stefano Fracchiolla, Monica Bocchia, Silvia Imbergamo, Catello Califano, Giuseppe Rodolfo Nunziata, Mario Annunziata, Antonino Mule', Patrizia Zappasodi, Fabio Giglio, Daniela Pietrasanta, Matteo Della Porta, Maurizio Musso, Monia Lunghi, Francesco Zaja, Elisabetta Todisco, Claudia Maria Basilico, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà

Blood (2025) 146 (Supplement 1): 439.

https://doi.org/10.1182/blood-2025-439

Published: 2025

Journal Articles

Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2024-194632

Published: 2024

Journal Articles

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Blood (2024) 144 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2024-207660

Published: 2024

Journal Articles

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Blood (2024) 144 (Supplement 1): 5188.

https://doi.org/10.1182/blood-2024-205427

Published: 2024

Journal Articles

Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 749.

https://doi.org/10.1182/blood-2024-194657

Published: 2024

Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli

Blood (2023) 142 (Supplement 1): 654.

https://doi.org/10.1182/blood-2023-172590

Published: 2023

Journal Articles

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Blood (2023) 142 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2023-184614

Published: 2023

Journal Articles

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Blood (2023) 142 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2023-184851

Published: 2023

Journal Articles

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Emilio Iannitto, Monica Balzarotti, Maurizio Martelli, Pier Luigi Zinzani, Alessandra Tucci, Alice Di Rocco, Federica Cavallo, Sara Usai, Anna Guidetti, Emanuele Ravano, Franceso Merli, Barbara Botto, Matteo Pelosini, Cristina Tecchio, Michele Spina, Enrico Derenzini, Silvia Finotto, Brunella Mola, Antonio Pinto, Manuela Zanni, Roberta Battistini, Stefan Hohaus, Irene Dogliotti, Guido Gini, Vittorio Ruggero Zilioli, Sonya De Lorenzo, Anna Dodero, Alessandro Broccoli, Alessandro Maggi, Clara Mannarella, Annalisa Chiarenza, Domenico Pastore, Pellegrino Musto, Caterina Stelitano, Francesco Di Raimondo, Nicola Cascavilla, Nicola Di Renzo, Marilena Salerno, Renato Scalone, Luca Nassi, Attilio Guarini, Caterina Patti, Vita Polizzi, Gabriella Amato, Giovannino Ciccone, Andrea Evangelista, Agostino La Porta, Angelo Genua, Donato Mannina, Ciro Maria Improta, Alessandro Re, Fabrizio Lo Presti, Rosalba Donatella Calogero, Maurizio Musso, Ugo Consoli

Blood (2023) 142 (Supplement 1): 986.

https://doi.org/10.1182/blood-2023-178197

Published: 2023

Journal Articles

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Blood (2023) 142 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2023-189300

Published: 2023

Journal Articles

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Massimo Offidani, Michele Cavo, Daniele Derudas, Francesco Di Raimondo, Antonio Cuneo, Luca Baldini, Roberta Della Pepa, Maurizio Musso, Mario Boccadoro, Pellegrino Musto, Maria Teresa Petrucci, Angelo Belotti

Blood (2022) 140 (Supplement 1): 7222–7223.

https://doi.org/10.1182/blood-2022-166399

Published: 2022

Journal Articles

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Blood (2022) 140 (Supplement 1): 10622–10623.

https://doi.org/10.1182/blood-2022-162298

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Interim analysis of PRO-MIND: Consistent quality of life in elderly patients with R/R DLBCL receiving tafasitamab and lenalidomide

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly diagnosed patients with light-chain amyloidosis: Interim analysis from an Italian, multicenter, retro-prospective real-world experience

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Hematopoietic Stem Cell Transplantation for Marginal Zone Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results

Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)

Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only